Inositol During Pregnancy: Benefits and Safety

Myo-inositol, the form of inositol most studied in pregnancy, appears to cut the risk of gestational diabetes roughly in half among women at elevated risk, and it does so with a safety profile that trials consistently describe as comparable to placebo. The supplement has also drawn attention for potential effects on preterm birth, blood pressure during pregnancy, and even neural tube defects that don’t respond to folic acid alone. Yet the strength of evidence varies sharply depending on which benefit you’re looking at, and the details of dosing, timing, and who stands to gain the most matter quite a bit.

How Inositol Fits into Pregnancy Metabolism

Inositol is a sugar alcohol your body already makes, and you also get it from foods like citrus fruits, beans, and whole grains. It plays a role in how cells respond to insulin, which is why researchers started looking at it for conditions involving insulin resistance. During pregnancy, insulin resistance rises naturally to shunt more glucose to the growing fetus, but when the system overshoots, the result can be gestational diabetes and the cascade of complications that follow.

The placenta itself both synthesizes inositol and actively transports it to the fetus. Research on placental tissue has shown that high blood sugar actually suppresses the transporters and enzymes involved in keeping inositol levels adequate, creating a vicious cycle: the more glucose rises, the less inositol the placenta can deliver.¹ On top of that, pregnant women lose substantially more inositol through the kidneys than non-pregnant women. In early pregnancy, urinary excretion of myo-inositol roughly triples, and by later gestation it rises more than fivefold.² Women who later develop gestational diabetes show even higher urinary losses in the first trimester, hinting that something in their inositol handling goes off-track early. Supplementation, in theory, compensates for those losses before the metabolic consequences pile up.

Gestational Diabetes Prevention

This is the area with the strongest and most consistent evidence. A meta-analysis pooling data from over 1,300 pregnant women found that starting inositol around the 12th to 13th week of pregnancy cut the risk of developing gestational diabetes by about 58 percent compared to placebo. When the analysis focused only on studies using myo-inositol specifically, the reduction was even steeper, around 70 percent.³ The trials behind these numbers enrolled women considered at higher risk, typically because of obesity, overweight, PCOS, or a family history of type 2 diabetes.⁴

One well-known randomized trial in obese pregnant women illustrates what that looks like in practice: 14 percent of women taking myo-inositol developed gestational diabetes versus about 34 percent in the control group. The myo-inositol group also saw a meaningful drop in insulin resistance as measured by the standard clinical index for it.⁵ That pattern, lower insulin resistance paired with fewer gestational diabetes diagnoses, shows up repeatedly across the literature.

A caveat worth noting: not every trial has been equally positive, and the most optimistic numbers come from Italian research groups that have been at the forefront of inositol research. A recent large trial in women with PCOS, published in JAMA, found that myo-inositol did not significantly reduce the composite rate of pregnancy complications in that specific population, though individual outcomes like gestational diabetes rates still trended in the expected direction.⁶ The overall body of evidence still points toward a real preventive effect, but the size of that effect in different populations remains a live question.

Blood Sugar Management When Gestational Diabetes Is Already Present

Preventing gestational diabetes is one thing; controlling blood sugar once it has been diagnosed is another. A smaller number of trials have looked at myo-inositol as an add-on for women who already have gestational diabetes. In one study of 69 women, taking 2 grams of myo-inositol twice daily improved fasting glucose, fasting insulin, and insulin resistance scores compared to a control group.⁷ Another randomized trial similarly found that myo-inositol supplementation led to significantly lower insulin resistance.⁸

These are encouraging results, but they don’t yet amount to evidence that myo-inositol can replace insulin or metformin for women who need medical treatment for gestational diabetes. The improvements tend to be modest, and the studies are small. Researchers have compared myo-inositol with metformin as preventive agents in high-risk women, and a narrative review of that literature suggests both show promise but neither has been proven definitively superior to the other.⁹ For now, myo-inositol is best understood as a supplement that may improve metabolic markers, not a standalone treatment for diagnosed diabetes.

Preterm Birth and Gestational Hypertension

Several trials designed primarily to test inositol’s effect on gestational diabetes noticed something interesting as a secondary finding: fewer preterm births in the supplementation groups. A pooled analysis of three randomized trials found that preterm birth occurred in about 3.4 percent of women taking myo-inositol compared to 7.6 percent in the control groups, cutting the odds of early delivery roughly in half.¹⁰ A review of the biological rationale pointed out that inositol participates in pathways related to uterine muscle contraction and inflammation, which could explain how it might delay premature labor.¹¹

A separate meta-analysis of myo-inositol in overweight and obese pregnant women also found significantly lower rates of gestational hypertension in the supplementation group.¹² Whether this is a direct effect on blood vessel function or an indirect benefit of better metabolic health isn’t fully resolved. Researchers are cautious about reading too much into these findings because preterm birth and hypertension were secondary outcomes in the trials, not what the studies were primarily powered to detect. Dedicated trials testing inositol specifically for preterm birth prevention haven’t been completed yet.

Neural Tube Defects and Folic Acid Resistance

Folic acid supplementation has dramatically reduced neural tube defects like spina bifida, but a subset of cases don’t respond to folic acid. Animal research going back decades suggested inositol might help fill that gap, and the first pilot human trial added some support. In that trial, women with a history of a neural-tube-defect-affected pregnancy took either inositol plus folic acid or placebo plus folic acid before and during early pregnancy. No neural tube defects occurred in the 14 pregnancies in the inositol group, while one case of anencephaly occurred among 19 pregnancies in the placebo group.¹³

Those numbers are obviously too small to prove anything by themselves, but the biological plausibility is strong. Inositol appears to support the closure of the neural tube through a biochemical pathway distinct from the one that folic acid uses, which is why researchers believe it could help specifically in the folic-acid-resistant cases.¹⁴ Larger trials are needed before inositol can be recommended for this purpose. Still, given the safety profile at the doses being used, some clinicians have already started offering it to women with recurrent neural tube defect histories as a supplement alongside folic acid rather than a replacement for it.

Safety During Pregnancy and for Newborns

The safety data on inositol in pregnancy is reassuringly consistent. A review of clinical trials testing inositol at doses from 4 to 60 grams per day for up to 12 months found that the only adverse events were mild gut symptoms, nausea, gas, and diarrhea, and those appeared only at doses above 12 grams per day.¹⁵ The typical dose used in pregnancy trials, 4 grams per day split into two doses, falls well below that threshold. A separate meta-analysis focused on overweight and obese pregnant women specifically reported no significant adverse events in the myo-inositol groups.¹⁶

For the baby, the large JAMA-published trial in women with PCOS provided useful data. Low Apgar scores at five minutes occurred at nearly identical rates in the myo-inositol and placebo groups, about 3 percent in each. Neonatal hypoglycemia requiring treatment was similarly rare and no different between groups.⁶ No trial to date has flagged any fetal or neonatal safety concerns with myo-inositol supplementation at standard doses. One area that remains underexplored is whether prenatal inositol supplementation has any lasting effects, positive or negative, on child development. A trial is currently underway evaluating a multi-nutrient intervention that includes myo-inositol and tracking infant growth, body composition, and neurodevelopment.¹⁷ Until those results come in, the existing data covers safety through birth but not beyond.

Myo-Inositol vs. D-Chiro-Inositol

Inositol comes in nine forms, but only two matter clinically: myo-inositol and D-chiro-inositol. Myo-inositol is by far the more abundant form in the body and the one used in most pregnancy research. D-chiro-inositol plays a complementary role in insulin signaling but behaves differently in the ovaries, where excessive amounts can actually interfere with egg quality. This is why the ratio between the two matters, especially in fertility contexts.

Most supplements marketed for pregnancy or fertility use myo-inositol alone. In the PCOS fertility space, a commonly studied ratio is 40:1 myo-inositol to D-chiro-inositol, which mirrors the natural blood ratio. Some products use a 3.6:1 ratio instead, and a small series of case reports in women undergoing IVF suggested this higher-DCI combination might contribute positively to outcomes in women with prior fertility treatment failures.¹⁸ More provocatively, one randomized trial comparing a higher-DCI combination against a lower-DCI combination in women with PCOS undergoing fertility treatment found significantly higher pregnancy and live birth rates in the higher-DCI group.¹⁹

The optimal ratio is still debated. For gestational diabetes prevention in women who are already pregnant, the evidence overwhelmingly uses myo-inositol alone at 2 grams twice daily, and that’s the safest recommendation to follow. If you have PCOS and are trying to conceive or undergoing fertility treatment, the ratio question is worth discussing with your reproductive endocrinologist, because the answer may differ from the standard pregnancy supplementation protocol.

Inositol and Egg Quality in IVF

Before pregnancy even begins, inositol has become a common supplement for women going through IVF, particularly those with PCOS. A meta-analysis of myo-inositol supplementation across IVF cohorts found that women taking it had more mature eggs and higher fertilization rates. The effect was strongest in women with PCOS: mature oocyte rates were roughly double those in the control group, and fertilization rates were also significantly improved.²⁰ Women who were poor ovarian responders, meaning they produced very few eggs regardless of stimulation, did not see a benefit in egg maturity, though their fertilization rates still improved.

A separate randomized trial in women undergoing IVF found significantly higher clinical pregnancy and live birth rates in the myo-inositol group.²¹ A Cochrane review looking at inositol for subfertile women with PCOS was less definitive. It initially suggested myo-inositol might lower miscarriage rates, but when one outlier study with an unusually high control-group miscarriage rate was removed, the effect disappeared.²² The takeaway is that myo-inositol likely improves egg quality metrics in PCOS but its effect on final pregnancy rates still needs to be confirmed in larger, well-controlled studies.

Mental Health During and After Pregnancy

Outside of pregnancy, high-dose inositol (12 to 18 grams per day) has been studied for panic disorder and depression, so a natural question is whether the lower doses used in pregnancy offer any mood benefits. The evidence here is mixed and leaning toward “probably not at these doses.” A large randomized trial testing a combined supplement containing myo-inositol, probiotics, and micronutrients from preconception through pregnancy found no effect on depression or anxiety scores during pregnancy or early postpartum.²³

However, when the same research group analyzed a subgroup of women who had elevated depression scores at baseline, the intervention group showed significantly better postpartum outcomes on measures of anxiety, depression, and overall mood.²⁴ Because the supplement included probiotics and other micronutrients alongside myo-inositol, it’s impossible to attribute the effect specifically to inositol. And subgroup analyses in clinical trials always carry the risk of being statistical flukes. If you’re pregnant and dealing with depression or anxiety, inositol supplementation is not a substitute for mental health care, but it’s interesting that the metabolic benefits don’t seem to come with any mood penalty.

Who Benefits Most and Practical Considerations

The research is clearest for women who enter pregnancy with at least one risk factor for gestational diabetes. That means women who are overweight or obese, women with PCOS, women with a family history of type 2 diabetes, and women who had gestational diabetes in a previous pregnancy. In these groups, starting myo-inositol supplementation around 12 to 13 weeks of pregnancy, at the standard dose of 2 grams twice daily, has the strongest evidence behind it.

For women without any of these risk factors, the evidence doesn’t clearly support routine supplementation. Most trials deliberately enrolled high-risk women, so extrapolating to the general pregnant population involves guesswork. That said, the safety data is reassuring enough that some practitioners take an “unlikely to hurt, might help” approach.

A practical note: most pregnancy-focused inositol supplements come as powder that dissolves in water, because the dose is bulky enough that capsules would require swallowing many pills. The standard 4 grams per day is well below the threshold where gastrointestinal side effects have been reported, so tolerance tends to be good. If you’re already taking metformin for insulin resistance or PCOS management, talk to your provider before adding inositol, since both affect similar metabolic pathways and the interactions during pregnancy haven’t been thoroughly studied.

Dietary intake of inositol from food runs about 1 gram per day in a typical Western diet, which is a small fraction of the supplemental dose used in trials. Foods rich in inositol include cantaloupe, citrus fruits, beans, and whole-grain bread, but reaching therapeutic levels through diet alone isn’t realistic. This is one of those cases where the supplement delivers something qualitatively different from the food source simply because of the quantity involved.

What the Placenta Reveals About Timing

One underappreciated detail from the research is how early inositol metabolism goes awry in pregnancies that will eventually develop gestational diabetes. The finding that women destined to develop gestational diabetes already show abnormally high urinary inositol losses in the first trimester suggests that the metabolic disruption precedes the clinical diagnosis by months.² Most trials started supplementation at 12 to 13 weeks, but there’s a biological argument for starting even earlier in high-risk women, potentially from preconception, to replenish inositol stores before the metabolic demands of pregnancy ramp up.

The placental data reinforces this logic. When maternal blood sugar is elevated, the placenta’s ability to synthesize and transport inositol drops, starving the very system that helps regulate glucose homeostasis.¹ This creates a feedback loop that gets harder to break the longer it runs. Supplementing before that loop establishes itself could, in theory, be more effective than waiting until the second trimester. Several of the IVF-related trials already start inositol months before conception, and the multi-nutrient trial tracking infant outcomes begins supplementation from preconception as well.¹⁷ Whether earlier preconception supplementation translates into better outcomes than the 12-to-13-week start used in most gestational diabetes prevention trials hasn’t been directly tested in a head-to-head comparison.